Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Idarucizumab reversed dabigatran despite severe renal dysfunction

Eikelboom JW et al. ACC 18, the annual meeting of the American College of Cardiology, Abstract 1231M-11.

Key clinical point: Renal function had no impact on idarucizumab’s efficacy for dabigatran reversal.

Major finding: Complete dabigatran reversal occurred in 98% of patients with severe renal dysfunction who received idarucizumab.

Study details: Post hoc analysis of data from RE-VERSE AD, idarucizumab’s pivotal trial with 503 patients.

Disclosures: RE-VERSE AD was funded by Boehringer Ingelheim, the company that markets idarucizumab (Praxbind) and dabigatran (Pradaxa). Dr. Eikelboom has been a consultant to and has received research support from Boehringer Ingelheim, as well as from Bayer, Bristol-Myers Squibb, Daiichi-Sankyo, Janssen, and Pfizer.

Source: Eikelboom JW et al. ACC 18, the annual meeting of the American College of Cardiology, Abstract 1231M-11.

Read the article.

Citation:

Eikelboom JW et al. ACC 18, the annual meeting of the American College of Cardiology, Abstract 1231M-11.

This Week's Must Reads

Gene sequencing sheds light on outcomes in MPN, Grinfeld J et al. N Engl J Med. 2018;379:1416-30

Obesity lowers risk of death in PE patients, Khan Z et al. CHEST. 2018 Oct. doi: 10.1016/j.chest.2018.08.919

T cell infusion effective in PML, Muftuoglu M et al. N Engl J Med. 2018 Oct 11;379:1443-51

Post hoc analysis of SUSTAIN shows efficacy of crizanlizumab, Kutlar A et al. Am J Hematol. 2018 Oct 8. doi: 10.1002/ajh.25308

Must Reads in Bleeding Disorders

Laced synthetic cannabinoid leads to bleeding, Kelkar AH et al. N Engl J Med. 2018;379:1216-23.

Phase 3 data on emicizumab, Mahlangu et al. N Engl J Med. 2018;379:811-22

Integrated programs ease sickle cell pain, hospitalizations, Annual meeting of the Foundation for Sickle Cell Disease Research

Watch for RBC adhesion in men with sickle cell , Annual meeting of the Foundation for Sickle Cell Disease Research

FDA approves Jivi for hemophilia A, Package insert, news release